Expertise in
3
conditions

Changqing Zheng

39 Huaxiang Road, 
Shenyang, CN 
Expertise in
3
conditions
39 Huaxiang Road, 
Shenyang, CN 

Overview

Changqing Zheng practices practicing medicine in Shenyang, China.

Zheng is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Colitis, Hemorrhagic Proctocolitis, Ulcerative Colitis, and Viral Gastroenteritis.

They are actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 5 clinical trials.

Locations

39 Huaxiang Road, Shenyang, 110022, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-World Clinical Practice in China
Enrollment Status: Completed
Publish Date: July 22, 2024
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
A Multicenter, Randomized, Double-blind, Placebo Parallel Controlled Clinical Study on the Effecacy and Safety of Different Dosing Regimens of Hemay007 in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: March 01, 2024
Intervention Type: Drug
Study Drug: Hemay007
Study Phase: Phase 2
Evaluation of the Simplified Diagnosis Tool for Chinese IBS-C (Irritable Bowel Syndrome With Constipation) Patients
Evaluation of the Simplified Diagnosis Tool for Chinese IBS-C (Irritable Bowel Syndrome With Constipation) Patients
Enrollment Status: Completed
Publish Date: December 28, 2023
View 4 Less Clinical Trials

35 Total Publications

Knockdown of LOXL2 suppresses cuproptosis induced by H2O2 to inhibited the procession of ulcerative colitis.
Knockdown of LOXL2 suppresses cuproptosis induced by H2O2 to inhibited the procession of ulcerative colitis.
Journal: International immunopharmacology
Published: May 23, 2025

Frequently Asked Questions about Changqing Zheng

Is Changqing Zheng a top-rated expert for Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Changqing Zheng is classified as an Advanced expert for Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Changqing Zheng participate in research or clinical trials?

Yes. Changqing Zheng has published 35 articles and abstracts on conditions like Colitis. You can view a list of Changqing Zheng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zheng's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile